[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.201.14. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 249
Citations 0
Comment & Response
December 2016

Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides—Reply

Author Affiliations
  • 1Departments of Pharmacology and Biochemistry, University of Texas Southwestern, Dallas
JAMA Neurol. 2016;73(12):1502-1503. doi:10.1001/jamaneurol.2016.4335

In Reply As noted in my article,1 the development of antisense drugs has not been easy. Matsui and I have recently described at length2 some of these difficulties and the lessons they offer for contemporary science. Unfortunately, Bhagavati’s letter, while correctly appreciating that results should be treated skeptically, falls short in other respects.

×